The results obtained by our working laboratory group are in agreement with those of Kicman et al. [1], who also showed that MMP-26 levels were highest in patients with benign lesions (10.44 ng/mL) compared to patients with ovarian cancer (9.33 ng/mL) and healthy women (7.16 ng/mL). This evidence concerns the gene MMP26 and ovarian carcinoma.